SARS-CoV-2 Quantitative IgG+IgM Antibody Panel
COVID-19 antibody testing utilizes a serum sample to identify exposure to the SARS-CoV-2 virus, regardless of symptom presentation. The COVID-19 IgG + IgM Antibody Panel evaluates IgG and IgM reactivity separately, providing individual results for each. This may be useful for determining the current stage of infection.

This test is performed on a high-precision chemiluminescent immunoassay that has received FDA authorization under emergency use authorization (EUA).

In a human study of COVID-19 patients, the COVID-19 IgG + IgM Antibody Panel was found to meet the following specifications for sensitivity and clinical specificity:

100% Sensitivity
97.4% Specificity
@ >15 days post-infection

94.4% Sensitivity
98.3% Specificity
@ >15 days post-infection